Condition(s) treated: Obesity; Asthma

Enrollment status: Recruiting. Expecting to enroll 40 people.

Sponsor: National Jewish Medical and Research Center

Principal investigator(s) or official(s):
David Beuther, MD, Principal Investigator, Affiliation: National Jewish Medical and Research Center faculty

Overall contact:
Jennifer M Brandorff, BA, CIM, Phone: 303-398-1443, Email: brandorffj@njc.org

This research study is looking at the effects of weight loss, due to surgery or structured weight-loss program on lung function, inflammation in your body and lungs, asthma and asthma symptoms. This study is important because we will be better able to understand the effect of weight on lung functioning and asthma. Approximately 20 research subjects will be enrolling in this study at National Jewish.

Adults with asthma who has elected to undergo weight-reduction surgery may qualify for the participation. Involvement will last about 1 year.

Official title: The Effect of Medical and Surgical Weight Loss on Pulmonary Physiology and Airway

Study design: Observational, Longitudinal, Defined Population, Prospective Study

Minimum eligible age: 18 Years. Eligible gender(s): Both.

Criteria:

Inclusion Criteria:

• Adults (≥18yr) who report a physician’s diagnosis of asthma and have taken any asthma medication within the last 2 weeks.

• Obesity (Body Mass Index (BMI) ≥40, or ≥35 with comorbidities, as per published guidelines for qualification for bariatric surgery).

• Planned weight-loss surgery or structured weight-loss plan.

Exclusion Criteria:

• Tobacco use within one month.

• Qualifying lung-functioning.

• Qualifying oxygen saturation levels.

• Use of systemic corticosteroids (Prednisone) within one month.

• Presence of another chronic lung disease besides asthma (COPD, bronchiectasis, ILD, sarcoidosis, etc).

• Presence of another chronic systemic inflammatory disease (rheumatoid arthritis or other connective-tissue disease, chronic infection such as osteomyelitis, inflammatory bowel disease, chronic active hepatitis, etc). Subjects with osteoarthritis, stable coronary artery disease, hypertension, or diabetes mellitus will not be excluded.

• Presence of malignant neoplasm within the last 3 years (with the exception of non-melanoma skin cancer).

• Clinically significant left or right ventricular dysfunction.

• Severe pulmonary hypertension (high blood pressure).

• Untreated obstructive sleep apnea:

• Subjects with a current diagnosis of sleep apnea not being treated with CPAP or BiPAP will be excluded.

• Subjects with a current diagnosis of sleep apnea being treated adequately (as determined by the investigators) will be included.

• Prader-Willi syndrome

• A known endocrinopathy causing obesity (e. g., Cushing’s Syndrome).

Jennifer M Brandorff, BA, CIM, Phone: 303-398-1443, Email: brandorffj@njc.org

National Jewish Medical and Research Center, Denver, Colorado 80206, United States; Recruiting
Jennifer M Brandorff, BA, CIM, Phone: 303-398-1443, Email: brandorffj@njc.org
Juno Pak, BA, Phone: 303-398-1443, Email: pakj@njc.org
David Beuther, MD, Principal Investigator

Start date: November 2005
Last updated: November 29, 2006